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OBJECTIVES Because the renin-angiotensin-aldosterone system (RAS) modifies cardiovascular autonomic
regulation, we studied the possible associations between baroreflex sensitivity (BRS) and
polymorphism in the RAS genes.
BACKGROUND Wide intersubject variability in BRS is not well explained by cardiovascular risk factors or life
style, suggesting a genetic component responsible for the variation of BRS.
METHODS Baroreflex sensitivity as measured from the overshoot phase of the Valsalva maneuver and
genetic polymorphisms were examined in a random sample of 161 women and 154 men aged
41 to 61 years and then in an independent random cohort of 29 men and 37 women aged 36
to 37 years. An insertion/deletion (I/D) polymorphism of angiotensin-converting enzyme
(ACE), M235T variants of angiotensinogen (AGT) and two diallelic polymorphisms in the
gene encoding aldosterone synthase (CYP11B2), one in the promoter (2344C/T) and the
other in the second intron, were identified by polymerase chain reaction.
RESULTS In the older population, BRS differed significantly across CYP11B2 genotype groups in
women (10.1 6 4.5, 8.7 6 3.8 and 7.1 6 3.2 mszmm Hg21 in genotypes 2344TT, CT and
CC, respectively, p 5 0.003 and 11.1 6 4.4, 8.9 6 4.1 and 7.5 6 3.4 mszmm Hg21 in intron
2 genotypes 1/1, 1/2 and 2/2, respectively, p 5 0.002), but not in men. No comparable
associations were found for BRS with the I/D polymorphism of ACE or the M235T variant
of AGT. In the younger population, BRS was even more strongly related to the CYP11B2
promoter genotype (p 5 0.0003). The association was statistically significant both in men
(p 5 0.015) and in women (p 5 0.03).
CONCLUSIONS Common genetic polymorphisms in the aldosterone synthase (CYP11B2) gene is associated
with interindividual variation in BRS. (J Am Coll Cardiol 2000;35:194–200) © 1999 by the
American College of Cardiology
Impaired baroreflex sensitivity (BRS) is a predictor of
cardiovascular mortality (1,2), and experimental (3) and
clinical (4) data suggest that BRS associates with the
development of high blood pressure (BP) and may be an
important hereditary component in the pathogenesis of
essential hypertension (5). Baroreflex sensitivity varies
widely between healthy individuals (6,7). This is not well
explained by demographic variables, cardiovascular risk
factors or life style, suggesting a genetic component con-
tributing to BRS (7,8).
The renin-angiotensin-aldosterone system (RAS) has an
important role in cardiovascular homeostasis. It regulates
sodium balance and intravascular volume (9) and, in addition,
interacts with other BP control mechanisms, including the
sympathetic nervous system and baroreceptor reflexes (10).
Many of these actions are mediated by angiotensin II and
aldosterone, which both have been shown to impair BRS
(11–13).
Genes encoding components of RAS, such as the
angiotensin-converting enzyme (ACE), angiotensinogen
(AGT) and aldosterone synthase (CYP11B2), are potential
risk loci for cardiovascular diseases (9,14,15). We, therefore, set
out to study the possible associations between BRS and
polymorphisms in these genes in two groups of healthy subjects
randomly selected from ethnically homogeneous populations.
METHODS
Subjects. Population 1.
Oulu Project Elucidating Risk of Atherosclerosis
(OPERA) is a population-based, epidemiological study of
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cardiovascular risk factors (15). Subjects with no treatment
for hypertension were randomly selected by age stratifica-
tion from the register of the Social Insurance Institution
covering the whole population of the City of Oulu in
Northern Finland (106,500 inhabitants). Two hundred
fifty-nine men and 267 women volunteered to take part, the
overall participation rate being 87%.
All subjects were invited to be studied by Valsalva
maneuver and 24-hour ambulatory BP measurement and
483 participated. Participants with diabetes mellitus (n 5
22), coronary artery disease based on symptoms, medication
or ECG (n 5 35), atrial fibrillation (n 5 12), frequent
ectopic beats (n 5 8), inadequate ambulatory BP monitor-
ing (n 5 19) or inadequate Valsalva maneuver (n 5 72)
were excluded, after which a total of 315 individuals (161
women and 154 men, 60% of the original cohort) remained
for analyses. Of the women, 76 were classified as postmeno-
pausal since at least 6 months had passed after their latest
menstruation, but 28 of them were on estrogen or proges-
terone replacement therapy. Nine of the 85 premenopausal
women were taking these hormones. Past and current
medical history, smoking habits, alcohol consumption and
physical activity were assessed with a standardized health
questionnaire and leisure-time physical activity groups (1–5)
were formed as described (16). A clinical examination and
standard 12-lead electrocardiography were performed. Rou-
tine blood tests, including an oral glucose tolerance test,
were performed on each subject.
Population 2. The reproducibility of the associations
between BRS and genetic polymorphisms of CYP11B2 and
ACE was tested in another population sample consisting of
89 subjects aged 36 to 37 years apparently free of cardio-
vascular disease. The characterization of this study group,
including echocardiographic examination of the left ventri-
cle, laboratory tests for blood lipids and assessment of
habitual physical activity, smoking and ethanol consump-
tion by two-month daily recording, has been detailed earlier
(17,18). The subjects were also characterized for their heart
rate and BP responses to the Valsalva maneuver. The ECG
and BP recordings were analyzed for BRS by two of the
authors (A.Y. and K.E.J.A.) blinded to the genotypes and
other data. DNA was available for genotyping in 84
subjects, and the recordings of the Valsalva maneuver were
acceptable for BRS determination in 70 subjects; 66 subjects
(37 women and 29 men) had both types of data available for
statistical analyses.
The design of the tests was approved by the Ethical
Committees of the respective institutions, and all subjects
gave their informed consent.
Baroreflex sensitivity. For the assessment of BRS, the
subjects performed the Valsalva maneuver in a sitting
position by blowing into a rubber tube connected to an
aneroid manometer and maintaining an expiratory strain of
40 mm Hg for 15 s. The test was performed three times at
5 min intervals in Population 1 and 1 to 2 times in
Population 2. Otherwise, the test method and the data
analysis (19) were identical in the two study groups. In
short, noninvasive arterial BP was recorded on a beat-to-
beat basis, using the Finapres finger-cuff method (Ohmeda
Inc.,) (20) with the monitored finger held at heart level. The
ECG and continuous BP data were stored in a digital
format and analyzed later using a menu-driven software
package (CAFTS, Medikro Oy, Finland). A linear least-
mean-squares fitting method was employed to calculate
BRS from the overshoot phase after the Valsalva maneuver
as the slope of the linear relationship between the RR
interval (in ms) and the preceding systolic BP value (in mm
Hg) (19). Only regression lines with a correlation coefficient
.0.7 or p , 0.05 and an increase in BP .15 mm Hg were
accepted. Baroreflex sensitivity was calculated as a mean of
the results of all the accepted tests.
Genotyping of subjects. The insertion/deletion (I/D)
polymorphism in intron 16 of the ACE gene (chromosome
17q23) (21) and the methionine/threonine polymorphism
(M235T) in codon 235 of the angiotensinogen gene (AGT,
chromosome 1q42) (22) were detected by polymerase chain
reaction (PCR), using the conditions described previously
(15). The subjects were also genotyped by PCR for two
recently discovered polymorphisms in the aldosterone syn-
thase gene (CYP11B2, chromosome 8q22). The details of
the technique and the structure of the gene have been
described elsewhere (18,23). One of the polymorphisms is
located in the 59flanking region, or promoter, of CYP11B2,
344 nucleotides before the start of the protein-coding
sequence. This position can be either a cytosine (2344C) or
a thymidine (2344T). The other is in the second intron of
the gene. In some individuals, the usual sequence of this
intron has been almost entirely replaced by a sequence
typically found in the related gene, CYP11B1. Such re-
placement is termed gene conversion, and the alleles at this
locus will be referred to as 1 (conversion) and 2 (no
conversion). In Population 1, genotype data were missing in
the case of two men for CYP11B2, two women for ACE
and one woman for AGT polymorphism.
Blood pressure measurements. In Population 1, ambula-
tory BP was recorded using the fully automatic SpaceLabs
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195JACC Vol. 35, No. 1, 2000 Ylitalo et al.
January 2000:194–200 Baroreflex Sensitivity and Genetic Polymorphism
90207 oscillometric unit (SpaceLabs Inc., Redmond,
Washington), which was set to take a measurement every 15
minutes from 4:00 AM till midnight and every 20 min from
midnight till 4:00 AM. The accuracy and reproducibility of
BP readings obtained with this device have been established
previously (24). In Population 2, resting brachial artery cuff
BP was averaged over three measurements.
Statistical analysis. The Statistical Package for the Social
Sciences for Windows, release 6.0, was used for data
analysis. A chi-square test was used to assess the fit of the
observed allele frequencies to the Hardy-Weinberg distri-
bution. The coefficient of gametic linkage disequilibrium
was calculated by likelihood methods, and the coefficient
(D) was reported as the ratio of the unstandardized coeffi-
cient to its maximal value (25). Continuous data are given as
means standard deviation (SD) according to the genotypes.
Gender differences were assessed by Mann-Whitney U test.
The differences between the variables in the different geno-
type groups were tested with analysis of variance (ANOVA)
(the Kruskal-Wallis test). A two-way ANOVA (3 3 3
factorial design) with Bonferroni’s corrections for multiple
comparisons was used to test the potential synergistic effect
of the ACE and AGT genes on BRS. Multiple regression
analysis was used to assess the quantitative effects of age,
BP, heart rate, body mass index, physical activity (log-
transformed), alcohol consumption (log-transformed),
smoking, serum cholesterol level and the use of estrogen or
progesterone therapy on BRS. The regression analysis was
made separately for men and women. The correlations
between variables were evaluated by Spearman’s correlation
coefficient. A value of p , 0.05 was considered statistically
significant.
RESULTS
Population 1. Main characteristics, 24-h BP, lifestyle data
and 2344C/T genotype in men and women are shown in
Table 1. There were no significant genotypic effects on any
variables, including BP. Similarly, the ACE and AGT
polymorphisms had no influence on any of these basic data
(not shown). The 24-h systolic (129 6 12 vs. 123 6
11 mm Hg, p , 0.001) and diastolic (81 6 8 vs. 77 6
7 mm Hg, p , 0.001) BPs were higher in men, but there
was no significant gender difference in body mass index.
Men were more often smokers and their total cholesterol
and triglyceride levels were higher and HDL cholesterol
lower those of women.
The frequencies of the I and D alleles were 0.46 and 0.54,
respectively; the frequencies of the M and T alleles were
Table 1. Main Characteristics of Men and Women in Different Genotype Groups by the
Promoter 2344 C/T Genotypes of CYP11B2: Population 1
CYP11B2 Genotype
TT CT CC
Men n 5 34 n 5 72 n 5 46
Age, yrs 50 (6) 49 (6) 50 (6)
Heart rate, b 69 (9) 70 (9) 70 (10)
Average 24-h systolic BP, mm Hg 129 (10) 128 (12) 131 (15)
Average 24-h diastolic BP, mm Hg 82 (7) 81 (8) 82 (8)
Body mass index, kg/m2 26 (3) 26 (3) 26 (3)
Smoking, n of smokers/all 15/34 24/72 14/46
Physical activity score‡ 2.9 (1.0) 3.0 (0.9) 3.2 (1.0)
Alcohol consumption, g/day 13.5 (14.9) 13.8 (12.2) 10.1 (11.7)
Total cholesterol, mmol/L 5.8 (1.0) 5.7 (1.1) 5.7 (0.9)
HDL cholesterol, mmol/L 1.3 (0.3) 1.2 (0.3) 1.2 (0.3)
Triglycerides, mmol/L 1.4 (0.7) 1.5 (0.8) 1.5 (0.6)
Women n 5 39 n 5 79 n 5 43
Age, yrs 51 (6) 50 (6) 52 (6)
Heart rate, b 73 (9) 72 (8) 73 (9)
Average 24-h systolic BP, mm Hg 121 (12) 124 (11) 123 (9)†
Average 24-h diastolic BP, mm Hg 76 (8) 77 (7) 76 (7)†
Body mass index, kg/m2 26 (4) 26 (4) 24 (3)
Smoking, n of smokers/all 9/39 25/79 12/43*
Physical activity score‡ 3.2 (0.9) 3.2 (0.9) 3.1 (0.8)
Alcohol consumption, g/wk 3.7 (6.9) 3.0 (3.8) 3.8 (5.7)†
Total cholesterol, mmol/L 5.5 (1.1) 5.5 (1.1) 5.4 (1.0)*
HDL cholesterol, mmol/L 1.6 (0.4) 1.5 (0.4) 1.5 (0.3)†
Triglycerides, mmol/L 1.1 (0.4) 1.1 (0.5) 1.1 (0.4)†
BP indicates blood pressure. All values means (SD) except for smoking. *p , 0.05 and †p , 0.001 between men and women.
‡Score 1–5, where 5 5 highly active and 1 5 sedentary. No differences were found between genotypes and analyzed by gender.
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0.53 and 0.47, respectively, and the frequencies of 2344T
and 2344C were 0.49 and 0.51, respectively. The genotype
distributions of all polymorphisms were in agreement with
the Hardy-Weinberg equilibrium both in men and in
women. The promoter 2344C/T and intron two conver-
sion polymorphisms occurred in linkage disequilibrium in
the CYP11B2 gene (D 5 0.48, x2 5 47.0, p , 0.0001).
The 2344CC, 2344CT and 2344TT genotypes were
found in 23%, 48% and 28% in Population 1, respectively.
The genotype distribution of the 2344C/T polymorphism
in 72 subjects with inadequate Valsalva maneuver was
similar to that in 315 subjects with adequate tests (20 [30%]
in 2344TT, 39 [45%] in CT and 13 [25%] in CC
genotype).
Baroreflex sensitivity was significantly lower in women
than in men (8.6 6 4.0 and 11.0 6 4.8 mszmm Hg21,
respectively, p , 0.0001). In women, BRS was related to
the CYP11B2 promoter genotype, averaging 10.1 6 4.5,
8.7 6 3.8 and 7.1 6 3.2 mszmm Hg21 in the 2344TT, CT
and CC groups, respectively (p 5 0.003) (Fig. 1); a
comparable association was observed between BRS and the
intron 2 polymorphism (1/1: 11.1 6 4.4; 1/2 8.9 6 4.1; 2/2:
7.5 6 3.4 mszmm Hg21, p 5 0.002). In men, by contrast,
BRS was unrelated to either the promoter genotype (Fig. 2)
or the intron 2 genotype (data not shown) of the CYP11B2
gene. In women, the association of BRS with the CYP11B2
promoter genotype was consistent with a gene dosage effect,
such that BRS increased in a linear relationship with the
number of 2344T alleles carried by each woman (F 5 13.1,
df1, p 5 0.0004, R2 5 0.08).
There were no significant differences in BRS between the
different genotypes of ACE or AGT in women or men.
When ACE and AGT were added as factors in ANOVA
(3 3 3 factorial design), no significant synergistic effect of
the AGT and 2344C/T genotypes on BRS was observed.
In univariate analysis, BRS was associated with 24-h
systolic BP in both men (r 5 2.22, p , 0.05) and women
(r 5 20.30, p , 0.0001). Baroflex sensitivity was also
weakly related to age in men (r 5 20.18, p , 0.05) but not
in women (r 5 20.13, ns). The association between BRS
and the different genotypes of the CYP11B2 2344C/T
promoter polymorphism in age tertiles in women is dis-
played in Figure 3. Although the same trends were seen in
all age tertiles, the association was only significant among
the women aged 41 to 46. All but two women in this tertile
were premenopausal.
In multiple regression analysis of the female population,
BRS was related to 24-h systolic BP (beta 5 0.38, p 5
0.0067) and the 2344C/T genotype of CYP11B2 (CC 5 1,
CT 5 2, TT 5 3; beta 5 0.37, p 5 0.008) but was
independent of age (beta 5 20.10, p 5 0.45), body mass
index (beta 5 20.14, p 5 0.33), physical activity (score 1–5;
beta 5 0.03, p 5 0.81), daily alcohol consumption (beta 5
0.03, p 5 0.82), smoking (nonsmoker 5 1, smokers 5 2;
beta 5 0.07, p 5 0.63), serum cholesterol (beta 5 20.20,
p 5 0.12), heart rate (beta 5 20.01, p 5 0.99) and the use
of estrogen or progesterone therapy (no therapy 5 1, on
therapy 5 2; beta 5 223, p 5 0.07). In men, only 24-h
systolic BP was an independent predictor (beta 5 0.39, p 5
0.013), while the other variables did not enter the model.
Different assumptions about the type of the genotype effect
did not alter the findings.
Population 2. The genotype distributions and baseline
characteristics of the study population have been described
in full detail previously (17,18). There were no significant
differences in gender distribution, body mass index, heart
Figure 1. Individual data on baroreflex sensitivity in relation to the
2344C/T polymorphism in the promoter of CYP11B2 in women
in Population 1. Horizontal lines indicate group mean values. * 5
ANOVA; CYP11B2 5 aldosterone synthase.
Figure 2. Individual data on baroreflex sensitivity in relation to the
2344C/T polymorphism in the promoter of CYP11B2 in men in
Population 1. Horizontal lines indicate group mean values. * 5
ANOVA; CYP11B2 5 aldosterone synthase.
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rate, BP, physical activity, smoking, ethanol consumption of
blood lipids across the 2344C/T genotype groups (18). Nor
did the ACE I/D polymorphisms have any influence on
these basic data (17). The 2344C/T genotypes of 18
subjects with inadequate Valsalva maneuver were 3 (17%)
2344TT, 8 (44%) CT and 7 (39%) CC.
In the total population of 37 women and 29 men,
ANOVA revealed a significant main effect of the 2344C/T
genotype on BRS (Fig. 4). The data were consistent with a
gene dosage effect; BRS increased in a linear relationship
with the number of 2344T alleles carried by each subject
(F 5 21.1, df1, p , 0.0001, R2 5 0.25). The association of
BRS with the 2344C/T genotype was statistically signifi-
cant in both men (TT: 20.2 6 10.8; CT: 12.6 6 6.5; CC:
10.0 6 2.7 mszmm Hg21, p 5 0.037, ANOVA) and
women (TT: 18.1 6 9.4; CT: 13.0 6 4.0; CC: 9.6 6
5.0 mszmm Hg21, p 5 0.017, ANOVA).
In women, BRS was also related to the intron two
polymorphism of CYP11B2, averaging 18.9 6 10.5, 14.6 6
6.3 and 10.8 6 3.9 mszmm Hg21 in the 1/1, 1/2 and 2/2
genotype groups, respectively (p 5 0.036, ANOVA). The
comparable trend in men was not statistically significant
(data not shown). There were no differences in BRS
between the I/D genotype groups of ACE in either women
or men (data not shown). The sex difference in BRS did not
reach statistical significance (14.7 6 8.3 in men and 13.5 6
6.3 mszmm Hg21 in women, p 5 0.47).
In multiple regression analysis, BRS was related to the
2344C/T genotype of CYP11B2 (CC 5 1, CT 5 2, TT 5
3; beta 5 0.49, p , 0.001), but was independent of sex
(male 5 1, female 5 2, beta 5 0.12, p 5 0.34), body mass
index (beta 5 0.02, p 5 0.92), serum cholesterol (beta 5
0.11, p 5 0.40), heart rate (beta 5 20.15, p 5 0.32),
systolic BP (beta 5 20.09, p 5 0.56), left ventricular mass
(beta 5 20.02, p 5 0.91), average daily physical activity
(expenditure of metabolic equivalents; beta 5 0.11, p 5
0.37), smoking (nonsmoker 5 0, 1–10 cigarettes/day 5 1,
.10 cigarettes/day 5 2; beta 5 0.13, p 5 0.32) and average
daily alcohol consumption (beta 5 0.05, p 5 0.69).
DISCUSSION
This study is the first to suggest that variation in a specific
gene may influence interindividual variation in BRS. The
observed associations between polymorphisms of the aldo-
sterone synthase gene (CYP11B2) and BRS were not
explained by any potentially confounding factor and were
particularly clear in a highly homogeneous younger popu-
lation. Our findings agree well with the earlier experimental
and clinical data suggesting a hereditary background for the
wide interindividual variation of BRS (3–5).
CYP11B2 polymorphism and cardiovascular regulation.
Thus far, there is limited information available concerning
the effects of CYP11B2 gene variation on cardiovascular
structure and function (9,23). A recent report of studies in
Population 2 suggested that the 2344CC genotype is a
Figure 3. Baroreflex sensitivity (mean 6 SEM) by the 2344C/T
polymorphism in the promoter of CYP11B2 in age tertiles in
women in Population 1. * 5 ANOVA; CYP11B2 5 aldosterone
synthase.
Figure 4. Individual data on baroreflex sensitivity in relation to the
2344C/T polymorphism in the promoter of CYP11B2 in Popu-
lation 2. Horizontal lines indicate group mean values. * 5
ANOVA; CYP11B2 5 aldosterone synthase.
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powerful predictor of increased left ventricular mass and
relatively impaired left ventricular diastolic function (18).
This association was not confirmed by the study with older
subjects having cardiovascular diseases, hypertension and
diabetes (26). The relationship between BRS and the
CYP11B2 genotypes observed in this study was, however,
independent of left ventricular mass (18). Thus, the
2344CC genotype may associate independently with low
BRS and left ventricular hypertrophy, both of which predict
increased cardiovascular mortality (1,2,27,28).
The association of BRS with CYP11B2 gene variation
initially came out in a study of more than 500 randomly
selected middle-aged nonhypertensive subjects (Population
1). Since multiple testing for genetic associations may
notoriously lead to chance findings even in nonmixed
populations, we repeated the study in a fully independent
population-based sample of younger healthy subjects (Pop-
ulation 2). In support of our primary data, an even stronger
association of BRS with the CYP11B2 genotypes was
observed, this time not only in women, but also in men.
Although only systolic BP and not age was related to BRS
in multivariate models in Population 1, aging and BP have
had independent effects on BRS in other studies
(1,6,29,30), suggesting that the influence of polymorphisms
on BRS may be filtered out upon aging in subjects with
higher BP values (31).
Gender-related differences. The genotypic effects were
analyzed separately for both genders because several previ-
ous studies have shown significant gender-related differ-
ences in the baroreceptor reflex control of heart rate in
various populations (32–36). In Population 1, an association
between BRS and the 2344C/T genotypes was observed
only among women and, furthermore, mainly in those
younger than 46 years who were predominantly premeno-
pausal. The observed gender difference in the genomic effect
among the middle-aged subjects is physiologically plausible
in the light of the prior studies and analogous to the
well-established gender difference in BRS and BP regula-
tion (33–36). Sex hormones may modulate the effects of
circulating angiotensin II, aldosterone and cortisol at the
receptor level in the central nervous system and interact with
components of tissue RAS in the brain, heart, vascular bed
and adrenals (37). We do not know why there was a gender
difference in the association between BRS and the
2344C/T genotypes in Population 1 but not in Population
2. However, the subjects in Population 1 were older, and
their BP and body mass index were higher which differences
may have modified the genetic influences on BRS.
Study limitations. The molecular mechanisms underlying
the association between BRS and CYP11B2 polymorphism
cannot be deduced from this study. Unfortunately, plasma
concentrations of RAS hormones were not available for the
populations we studied. However, it is reasonable to spec-
ulate that one of the CYP11B2 polymorphisms we exam-
ined, or an additional polymorphism in linkage disequilib-
rium with it, alters CYP11B2 gene expression in the adrenal
cortex and thus influences plasma aldosterone levels which
in turn affect BRS. Indeed, intravenous infusion of aldoste-
rone impairs BRS in both animal models and man (12,13).
Prognostic information on the role of baroreflex function
is based on phenylephrine-based BRS measurements (1,2).
The predictive significance of BRS data obtained from a
Valsalva maneuver is unknown, but the measurements are
reproducible and correlate closely with indexes derived using
the invasive phenylephrine method (19,38–40). Indeed, the
stimulus to arterial baroreceptors obtained by the relatively
high expiratory pressure (40 mm Hg) in the Valsalva
maneuver is close to the stimulus obtained by a phenyleph-
rine injection (38), and when the baroreflex slope is ana-
lyzed, as it is in this study, from the overshoot phase of the
Valsalva maneuver (39), it is likely that the results of these
two methods are comparable. Importantly, we only analyzed
healthy subjects without apparent cardiac diseases which
improves the accuracy and eliminates pitfalls of the Valsalva
test (41).
Conclusions. Genetic variation in the aldosterone synthase
(CYP11B2) gene is associated with interindividual variation
in BRS. Because low BRS is a marker of increased risk of
cardiovascular morbidity and mortality, the clinical and
prognostic significance of CYP11B2 polymorphism merits
further investigation.
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